CDK4 and breast carcinoma: In this study, we use real-world evidence to assess the use and effectiveness of everolimus exemestane as first-line, second-line, or third-line therapy following prior endocrine therapy alone vs endocrine therapy + CDK4/6i in patients with metastatic hormone-positive HER2− breast cancer.